Equities

PainReform Ltd

PRFX:NAQ

PainReform Ltd

Actions
Health CarePharmaceuticals and Biotechnology
  • Price (USD)0.7711
  • Today's Change0.019 / 2.47%
  • Shares traded561.29k
  • 1 Year change-96.64%
  • Beta0.5733
Data delayed at least 15 minutes, as of Sep 20 2024 20:59 BST.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Profile data is unavailable for this security.

About the company

PAINREFORM LTD is a Israel-based pharmaceutical Company. The Company’s main activity is to develop reformulation of established pain therapeutics. PainReform Ltd provides technology, which is dedicated to prolong and enhance efficacy, minimize adverse effects and increase patients convenience as well as faster return of motor function.

  • Revenue in USD (TTM)0.00
  • Net income in USD-17.67m
  • Incorporated2007
  • Employees6.00
  • Location
    PainReform Ltd65 Yigal Alon St.TEL AVIV-YAFO 6744316IsraelISR
  • Phone+972 37177051
  • Fax+972 99542266
  • Websitehttps://painreform.com/
More ▼

Peer analysis

Key Information
CompanyRevenue (TTM)Net income (TTM)Market capEmployeesPrice/earnings (TTM)Price/book value (MRQ)Price/cash flow (TTM)Price/sales (TTM)EPS (excl. extraordinary items, TTM)EPS (incl. extraordinary items, TTM)Revenue per share (TTM)Book value per share (MRQ)Asset turnover (TTM)Inventory turnover (TTM)Receivables turnover (TTM)Revenues per employee (TTM)Return on avg assets (TTM)Return on avg assets (5 yr avg)Return on investment (TTM)Return on investment (5 yr avg)Gross margin (TTM)Gross margin
(5 yr avg)
Net profit margin (TTM)Net Profit margin
(5 yr avg)
Quick ratio (MRQ)Interest coverage (TTM)Total debt to capital (MRQ)Payout ratio
(5 yr avg)
Revenue
(YOY change %)
Revenue
(5 yr growth rate)
Net income
(YOY change %)
Net income
(5 yr growth rate)
Capital expenditure
(5 yr growth rate)
Dividend
(5 yr growth rate)
Life Stem Genetics Inc0.00-568.02k393.34k1.00--0.21-----0.013-0.0130.000.00760.00----0.00-198.83---330.32--------------0.0241--------------
ITonis Inc0.00-1.17m609.36k-----------0.0012-0.00120.00-0.00040.00-------187.63---1,169.36-------------0.8999---------506.86------
TRACON Pharmaceuticals Inc3.20m5.20m707.07k17.000.0547--0.13570.2213.793.791.39-0.90650.3267----188,235.3053.04-79.42---177.85----162.34-813.81---19.35------32.0587.68------
Resonate Blends Inc751.28k-1.88m797.05k6.00------1.06-0.0205-0.02050.0083-0.02440.632--11.93---158.40-680.29----46.92-78.88-250.64-12,895.26---2.304.00---66.73-56.57-316.63------
PainReform Ltd0.00-17.67m881.21k6.00---------41.92-41.920.00-3.530.00----0.00-309.43-55.47-650.22-68.20---------------------6.28------
Agentix Corp0.00-585.16k906.02k-----------0.0146-0.01460.00-0.06390.00-------318.23-----------------19.24--------57.41------
Bespoke Extracts Inc956.86k-1.36m966.01k10.00------1.01-0.1331-0.13310.0941-0.1942.2920.1021.3695,686.00-325.13------45.50---141.75--0.0482-53.38----22,933.72--63.98------
Evofem Biosciences Inc17.71m57.36m973.19k37.000.0007--0.01690.0549-0.4918-0.49180.0297-0.78031.571.813.61478,756.80534.21-211.64----75.75--341.16-1,031.550.0841-4.50----8.20--164.08---10.59--
CanaQuest Medical Corp0.00-812.13k1.05m-----------0.0517-0.05170.00-0.03720.00-------1,084.38--------------------------57.42------
Data as of Sep 20 2024. Currency figures normalised to PainReform Ltd's reporting currency: US Dollar USD

Institutional shareholders

25.71%Per cent of shares held by top holders
HolderShares% Held
Armistice Capital LLCas of 30 Jun 2024276.00k23.57%
Virtu Americas LLCas of 30 Jun 202420.06k1.71%
Osaic Wealth, Inc. (Investment Management)as of 30 Jun 20244.60k0.39%
UBS Securities LLCas of 30 Jun 2024432.000.04%
Citadel Securities LLCas of 30 Jun 20240.000.00%
More ▼
Data from 30 Jun 2024 - 30 Jun 2024Source: FactSet Research Systems Inc.
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.